The in vivo effects of PFK15 (a selective PFKFB3 inhibitor) on RA synovial inflammation and joint destruction have been evaluated in CIA mice: Intraperitoneal injection of PFK15 reduces the increase in clinical scores compared to DMSO treatment (93). The gene discussed is PFKFB3; the disease is rheumatoid arthritis.